5ZMQ

Crystal structure of Zika NS3 protease with phenylacetyl-Lys-Lys-Arg-COOH inhibitor

5ZMQ の概要

• エントリーDOI: 10.2210/pdb5zmq/pdb
• 関連するBIRD辞書のPRD_ID: PRD_002309
• 分子名称: Serine protease subunit NS2B, Serine protease NS3, peptide PAC-DLY-DLY-DAR, ... (4 entities in total)
• 機能のキーワード: viral protease, serine protease, non-structural protein 3, zika protease, viral protein, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Zika virus (ZIKV); 詳細
• タンパク質・核酸の鎖数: 10
• 化学式量合計: 100647.02

構造登録者

Phoo, W.W.,Wirawan, M. (登録日: 2018-04-05, 公開日: 2018-10-17, 最終更新日: 2024-10-23)

主引用文献

Phoo, W.W.,Zhang, Z.,Wirawan, M.,Chew, E.J.C.,Chew, A.B.L.,Kouretova, J.,Steinmetzer, T.,Luo, D.
Structures of Zika virus NS2B-NS3 protease in complex with peptidomimetic inhibitors.
Antiviral Res., 160:17-24, 2018

PubMed Abstract: Zika virus NS2B-NS3 protease plays an essential role in viral replication by processing the viral polyprotein into individual proteins. The viral protease is therefore considered as an ideal antiviral drug target. To facilitate the development of protease inhibitors, we report three high-resolution co-crystal structures of bZiPro with peptidomimetic inhibitors composed of a P1-P4 segment and different P1' residues. Compounds 1 and 2 possess small P1' groups that are split off by bZiPro, which could be detected by mass spectrometry. On the other hand, the more potent compound 3 contains a bulky P1' benzylamide structure that is resistant to cleavage by bZiPro, demonstrating that presence of an uncleavable C-terminal cap contributes to a slightly improved inhibitory potency. The N-terminal phenylacetyl residue occupies a position above the P1 side chain and therefore stabilizes a horseshoe-like backbone conformation of the bound inhibitors. The P4 moieties show unique intra- and intermolecular interactions. Our work reports the detailed binding mode interactions of substrate-analogue inhibitors within the S4-S1' pockets and explains the preference of bZiPro for basic P1-P3 residues. These new structures of protease-inhibitor complexes will guide the design of more effective NS2B-NS3 protease inhibitors with improved potency and bioavailability.

PubMed: 30315877
DOI: 10.1016/j.antiviral.2018.10.006

実験手法

X-RAY DIFFRACTION (1.987 Å)